Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BLFS vs FEMY: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BLFS Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)

BLFS Overall Winner 6-Pillar Tally: BLFS 6 – 0 FEMY Matrix Metrics: BLFS 9 – 1 FEMY

As of Nov 16, 2026, BioLife Solutions Inc. (BLFS) is the stronger overall head-to-head candidate over Femasys Inc. (FEMY) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BLFS carries a Unified Composite Score of 46.0/100 (HOLD) at $38.61 (117.0x Forward P/E, 6.0% operating margin), whereas FEMY carries 52.6/100 (HOLD) at $1.28 (N/M Forward P/E, -763.9% operating margin).

  • Composite vs. Pillar Nuance: While FEMY currently prints a higher short-term Unified Composite Score (52.6/100 HOLD vs. BLFS 46.0/100 HOLD), BLFS captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (6.0% vs. -763.9% operating margin) and revenue trajectory (+21.5% vs. -18.9% YoY).
  • Technical & Structure Timing Caution: BLFS trades in a Markup technical trend (BREAKOUT options phase, RSI 60.5); meanwhile FEMY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BLFS vs FEMY
BLFS NASDAQ Head-to-Head Winner
BioLife Solutions Inc.
Electromedical & Electrotherapeutic Apparatus
$38.61
+3.51% 1D
Market Cap $1.8B
TTM Revenue $107M
Forward P/E 117.0x
Beta / 30D Vol 1.05β · 31% Vol
Unified Composite Score
46.0 / 100 HOLD
Tech 27.0 Fund 46.0 Flow 59.0 Mom 56.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (10.2% over 20 days), RSI 61
RSI-14: 60.5 · SMA20: $37.08 · SMA50: $35.70
FEMY NASDAQ
Femasys Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$1.28
-9.86% 1D
Market Cap $11.9M
TTM Revenue $2.3M
Forward P/E N/M
Beta / 30D Vol 4.01β · 72% Vol
Unified Composite Score
52.6 / 100 HOLD
Tech 61.0 Fund 62.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -21.5%), weak momentum, RSI 35
RSI-14: 34.6 · SMA20: $1.43 · SMA50: $1.92

6-Pillar Scorecard Institutional Category Breakdown (BLFS 6 – 0 FEMY)

Columns: Metric · BLFS · FEMY
1. Valuation Multiples BLFS
Forward P/E 117.0x N/M
Trailing P/E 37.3x N/M
PEG Ratio N/M N/M
EV / Revenue 17.0x 4.9x
2. Growth & Scale BLFS
Revenue Growth (YoY) +21.5% -18.9%
Earnings Growth (YoY) -13.9% +0.0%
TTM Revenue (USD) $107M $2.3M
Market Cap $1.8B $11.9M
3. Profitability & Quality BLFS
Gross Margin 63.6% 60.9%
Operating Margin 6.0% -763.9%
Net Profit Margin 54.4% 0.0%
Return on Equity (ROE) 12.8% -425.0%
4. Balance Sheet & Cash Flow BLFS
Cash Generation (TTM) -$2.2M -$19M
Cash Flow Margin -2.1% N/A
Net Cash / Leverage $8.3M Net Cash -$658,045 Net Debt (0.65x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BLFS
Options Structure Phase BREAKOUT UNCLASSIFIED
Current IV / %ile 40.1% (6th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat BLFS
OpEx & R&D Intensity 57.6% of Rev ($61M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Instruments & Supplies Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BLFS (9) vs FEMY (1)
Institutional Metric BLFS FEMY Criterion Row Edge
Market Capitalization
Scale
$1.8B $11.9M Larger Scale BLFS
Trailing P/E Ratio
Valuation
37.3x N/M Lower Multiple BLFS
Forward P/E Ratio
Valuation
117.0x N/M Lower Multiple BLFS
Revenue Growth (YoY)
Growth
+21.5% -18.9% Higher Growth BLFS
Operating Margin (TTM)
Profitability
6.0% -763.9% Higher Margin BLFS
Net Profit Margin
Profitability
54.4% 0.0% Higher Margin BLFS
Return on Equity (ROE)
Capital Efficiency
12.8% -425.0% Higher ROE BLFS
52-Week Range Position
Momentum
95% ($18–$40) 17% ($0–$6) Stronger Trend BLFS
Beta / 30D Volatility
Risk Regime
1.05β · 31% Vol 4.01β · 72% Vol Lower Realized Risk BLFS
Unified Institutional Score
Composite Signal
46.0 / 100 (HOLD) 52.6 / 100 (HOLD) Higher Composite FEMY
Trailing 12M Revenue (USD)
Operating Scale
$107M $2.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
63.6% 60.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 17.0x EV/Rev N/M PEG · 4.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$2.2M ($8.3M Net Cash) -$19M (-$658,045 Net Debt (0.65x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BLFS +42.66 pp
BLFS: +8.67% · FEMY: -33.99%
3M Horizon BLFS +86.04 pp
BLFS: +38.24% · FEMY: -47.8%
6M Horizon FEMY +269.74 pp
BLFS: +100.36% · FEMY: +370.1%
1Y Horizon FEMY +90.68 pp
BLFS: +53.58% · FEMY: +144.26%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period BLFS Revenue FEMY Revenue BLFS Op. Margin FEMY Op. Margin Margin Leader
FY2018 $20M N/A 18.5% N/A BLFS
FY2019 $30M N/A -0.8% N/A BLFS
FY2020 $50M $0M -13.0% -668.0% BLFS
FY2021 $120M $0M -29.5% -706.7% BLFS
FY2022 $80M $0M -7.8% -961.7% BLFS
FY2023 $70M $0M -25.3% -1353.4% BLFS
FY2024 $70M $0M -6.0% -1091.8% BLFS
FY2025 $100M $0M -17.3% -767.0% BLFS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BLFS BREAKOUT
38d in phase · OBV ACCUMULATION
Current IV 40.1%
IV Percentile 6th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact BLFS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
FEMY UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact FEMY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BLFS Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $1.8B market capitalization and 6.0% operating margin.
OpEx & R&D Reinvestment 57.6% of Rev ($61M)
90D Engineering Disclosures 0 Published
FEMY Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $11.9M market capitalization and -763.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BLFS vs FEMY Key Questions & Quantitative Answers

As of Nov 16, 2026, BioLife Solutions Inc. (BLFS) is the stronger overall head-to-head candidate over Femasys Inc. (FEMY) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BLFS carries a Unified Composite Score of 46.0/100 (HOLD) at $38.61 (117.0x Forward P/E, 6.0% operating margin), whereas FEMY carries 52.6/100 (HOLD) at $1.28 (N/M Forward P/E, -763.9% operating margin). Composite vs. Pillar Nuance: While FEMY currently prints a higher short-term Unified Composite Score (52.6/100 HOLD vs. BLFS 46.0/100 HOLD), BLFS captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (6.0% vs. -763.9% operating margin) and revenue trajectory (+21.5% vs. -18.9% YoY). Technical & Structure Timing Caution: BLFS trades in a Markup technical trend (BREAKOUT options phase, RSI 60.5); meanwhile FEMY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BLFS leads the Growth & Scale pillar: BLFS posts +21.5% YoY revenue growth and -13.9% YoY earnings growth on $107M TTM revenue (63.6% gross margin, 6.0% operating margin), compared with FEMY at -18.9% YoY revenue growth and +0.0% YoY earnings growth on $2.3M TTM revenue (60.9% gross margin, -763.9% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), BLFS cumulative revenue shifted +400.0% while FEMY shifted N/A. In operating R&D and SG&A reinvestment, BLFS deploys 57.6% of Rev ($61M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for FEMY.

BLFS screens cheaper on headline valuation multiples. BLFS trades at 117.0x Forward P/E, 37.3x Trailing P/E, N/M PEG, and 17.0x EV/Revenue (-2.1% FCF margin), whereas FEMY trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 4.9x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BLFS (12.8% ROE) versus FEMY (-425.0% ROE) capital efficiency.

In options market volatility and institutional positioning, BLFS carries 40.1% implied volatility (6th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.05β · 31% Vol realized risk). By comparison, FEMY carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.01β · 72% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.